Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015
Jamjoom Pharmaceuticals Factory — 9M 2024 Earnings Presentation
18 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Oct 27, 2024
Slide 1: Earnings Presentation 9M 2024
Earnings Presentation 9M 2024 Jeddah | 27 October 2024
Slide 2: Disclaimer
2 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is
Slide 3: Business and Strategy Highlights
Business and Strategy Highlights
Slide 4: YTD performance highlights: Revenue crosses SAR 1Bn, NP Margin at 28.8%
4 Business and Strategy Highlights YTD performance highlights: Revenue crosses SAR 1Bn, NP Margin at 28.8% Revenue # of Brands Strong momentum driven by robust sales 9 new launches this year including 4 in 9M 24 +19% YoY across key therapeutic areas (TAs) and 3Q 24 +8% YoY Consumer Health and 2 in A
Slide 5: YTD key highlights and outlook
6 Business and Strategy Highlights YTD key highlights and outlook Saudi Market • Overall retail market grew +16.1% (11.5% ex-weight loss diabetes drugs)1 • Tender sales growing +41% YTD (Overall KSA sales grew +17%) • Iraq (+17%) and Gulf (+19%) continue to make solid contributions International Mar
Slide 6: Jeddah sterile facility fully operational whilst Egypt ramps up production
7 Business and Strategy Highlights Jeddah sterile facility fully operational whilst Egypt ramps up production SAR 100bn+ of Total Addressable Market Jeddah Jeddah Cairo Algiers* in Core Geographies By 2027 Main Facility Sterile Facility Main Facility Facility Iraq Kuwait Bahrain Egypt Qatar Kingdom
Slide 7: Accelerating revenue growth in strategic therapeutic areas and regions
8 Business and Strategy Highlights Accelerating revenue growth in strategic therapeutic areas and regions Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +19% 22 13 13 17 1,059 102 892 +19% +64% units sold 13 1,059 c.61% local mfg. 15 8 8 26 17 33 4
Slide 8: Monthly revenue growth for top KSA pharma in the last 32 months
9 Business and Strategy Highlights Monthly revenue growth1 for top 5 KSA pharma in the last 32 months Peer 1 12 negative months Peer 2 6 negative months 1 negative month Peer 3 11 negative months Peer 4 15 negative months Jan-22 Jul-22 Dec-22 Jul-23 Dec-23 Aug-24 2022 2023 2024 Growth vs same month
Slide 9: Pipeline overview
10 Business and Strategy Highlights Pipeline overview Under SFDA review Ready for SFDA Submission Under Development Total 2 Ophthalmology 4 14 8 3 General Medicine 1 4 Dermatology Revenue growth EBITDA 3 margin 3 4 Consumer Health 6 12 2 Gastrointestinal 2 6 4 1 Cardiovascular Dividend 1 8 CAPEX 6 g
Slide 10: Strategic portfolio diversification to propel JP into strategically viable TAs
11 Business and Strategy Highlights Strategic portfolio diversification to propel JP into strategically viable TAs 2021 Revenue Contribution by Therapeutic Area (SARmn) 9M 2024 Revenue Contribution by Therapeutic Area (SARmn) Pain & Inflammation 26% C. Nervous System 5% Anti-diabetic 1% Ophthalmolog
Slide 11: Financial Highlights
Lejla pgana Jamjoom Pharma Financial Highlights
Slide 12: 3rd Quarter 2024 highlights
13 Financial Highlights 3rd Quarter 2024 highlights Revenue (SARmn) EBITDA (SARmn) +12% +23% 328 112 293 91 EBITDA Margin 31.2% 33.1% 33.4% 34.1% 33.8% 35.4% 3Q 23 3Q 24 3Q 23 3Q 24 FCF (SARmn) Net Profit (SARmn) +23% +38% 95 101 77 73 FCF conversion 80.4% 93.4% 87.5% 90.7% 87.4% 84.1% Net Profit Ma
Slide 13: Operational efficiency to counter rising costs…
14 Financial Highlights Operational efficiency to counter rising costs… Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +6% 305 22 324 (1) (1) +29% R&D/Sales decreased to 8 5 397 2.3% from 2.9% in 9M23 17 60 -5% +9% -2% 307 9M 23 R&D Selling & Distribution General
Slide 14: … and deliver sustainable growth in profitability
15 Financial Highlights … and deliver sustainable growth in profitability EBITDA Movement YoY (SARmn) EBITDA and Net Profit Margins, Quarterly (%) +26% 167 EBITDA Margin 35.4% 34.5% 33.8% 34.1% 31.2% EBITDA Margin 18 365 32.5% 1 25.9% 30.9% (90) 290 (22) 29.0% 26.4% 26.7% 21.3% Includes income from
Slide 15: Balancing cash flow efficiency with strategic business growth
16 Financial Highlights Balancing cash flow efficiency with strategic business growth Cash Conversion Cycle (Days) ▪ Cash conversion cycle expanded by a CAGR of 4.6% since 9M 2022, while revenue CAGR was 21.3%. This reflects our strategic balance of inventory +5% buildup and efficient receivables ma
Slide 16: Outlook and Guidance
Layla pagans Jamjoom Pharma Outlook and Guidance
Slide 17: Financial guidance: Reiterating our 2024 targets
18 Outlook and Guidance Financial guidance: Reiterating our 2024 targets FY 24 Guidance 9M 2024 Actual Results FY 25-26 Guidance Revenue growth 15-18% 18.7% 12-15% EBITDA margin 31-32.5% 34.5% 30.0-31.5% CAPEX 4-6% 4.4% 4-6% Dividend 1H 2024 dividend of SAR 1.6/share 50-60% payout ratio 50-60% payou
Slide 18: Q&A Session
Q&A Session Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR
Jamjoom Pharmaceuticals Factory — 9M 2024 Earnings Presentation on 6ix